Accretion Nutraveda IPO
Market Sentiment
Market Lot Size
IPO Details
IPO Reservation
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3.07 | 5.20 | 16.06 | 14.07 |
| Expense | 2.78 | 4.28 | 12.87 | 11.20 |
| Profit (PAT) | 0.28 | 0.82 | 2.61 | 2.33 |
| Total Assets | 4.06 | 4.64 | 10.86 | 16.35 |
| Company | P/E | EPS | Market Cap (Cr) |
|---|---|---|---|
| Walpar Nutritions Ltd. | 23.94 | 1.80 | 11 |
| Influx Healthtech Limited | 25.93 | 7.31 | 37 |
Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 53,20,000 | 100.00% |
| Promoter Holding Post Issue | 72,40,000 | 73.48% |
Company Information
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company serves its customers in India as well as in international countries like Sri Lanka, Singapore, and the USA. The firm blends Ayurvedic and science to offer treatments for various areas, like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness. The company runs a 10,763 sq. ft. manufacturing facility situated in Gujarat. Its unit includes modern infrastructure and quality control systems.
| Purpose | Amount (Cr) |
|---|---|
| Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| Purchase of Machineries for New Manufacturing Setup | 8.03 |
| Funding working capital requirements of our company | 5.50 |
| General Corporate Purpose | - |
Resources & Documents
Accretion Nutraveda Ltd., 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand,, Ahmedabad, Gujarat, 382213
Accretion Nutraveda has set a price band of Rs 122–Rs 129 per share for an issue size of Rs 25 crore in the nutraceuticals sector. The stock listed with a 48.22% gain versus its issue price on February 04, 2026.
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company operates in the nutraceuticals space.
The issue is promoted by Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel with Sobhagya Capital Options Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Purchase of Machineries for Automation in existing Manufacturing unit (Rs 4 crore) and Purchase of Machineries for New Manufacturing Setup (Rs 8 crore).
Grey market is quoting a premium of +Rs 60 (+46.5% over issue price), up Rs 15 from the previous session. Final subscription data records overall subscription at 1.91x, retail at 2.19x, QIB at 1.01x, NII at 2.42x.
On fundamentals, the company is posting revenue growth of 208.9%, a profit margin of 16.3%, return on equity of 81.2% in its most recent reported period. Listed peers in this segment include Influx Healthtech Limited (P/E 25.93x, market cap Rs 37 crore) and Walpar Nutritions Ltd. (P/E 23.94x, market cap Rs 11 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Subscribe call — the composite picture tilts favourable, though not without some caveats. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!